| pubmed-article:9070486 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C0009402 | lld:lifeskim |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C1414864 | lld:lifeskim |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C0444956 | lld:lifeskim |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C0444889 | lld:lifeskim |
| pubmed-article:9070486 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:9070486 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9070486 | pubmed:dateCreated | 1997-4-15 | lld:pubmed |
| pubmed-article:9070486 | pubmed:abstractText | It has been suggested that there is a relationship between 5-fluorouracil (5-FU) dose levels and response rates. A bimonthly 2-day regimen of leucovorin (LV) and 5-FU bolus plus infusion has been found to be superior to a monthly 5-FU bolus with low dose LV. Based on these reports, a first-line Phase II study was performed in 101 patients with advanced colorectal carcinoma who were given a bimonthly combination of high dose LV and a high dose 48-hour infusion of 5-FU. | lld:pubmed |
| pubmed-article:9070486 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9070486 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9070486 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9070486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9070486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9070486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9070486 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9070486 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:9070486 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:FavreRR | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:KrulikMM | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:de GramontAA | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:BeerblockKK | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:LouvetCC | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:CaroliMM | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:RaymondEE | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:AndréTT | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:RinaldiYY | lld:pubmed |
| pubmed-article:9070486 | pubmed:author | pubmed-author:TournigandCC | lld:pubmed |
| pubmed-article:9070486 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9070486 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:9070486 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:9070486 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9070486 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9070486 | pubmed:pagination | 1100-5 | lld:pubmed |
| pubmed-article:9070486 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:meshHeading | pubmed-meshheading:9070486-... | lld:pubmed |
| pubmed-article:9070486 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9070486 | pubmed:articleTitle | Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). | lld:pubmed |
| pubmed-article:9070486 | pubmed:affiliation | Hopital Saint-Antoine, Paris, France. | lld:pubmed |
| pubmed-article:9070486 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9070486 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9070486 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9070486 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9070486 | lld:pubmed |
